Calendario›TCRX›A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
Ensayo de TScan Therapeutics, Inc. en Tumor solido.
Más ensayos de: Tumor sólido.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 12
- Centros
- 4
- Fin del objetivo primario
- dic 2024
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en feb 2021.
Lo que ha cambiado
Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.
| Visto | Qué se mueve | Cambio |
|---|---|---|
| 16 sep 2026 | Estado | Sin noticias del promotor → Completado |
Qué mide
Single Cell Sequencing (del registro, en inglés) (3 años)
Cómo lo describe el promotor
En el documentoEn inglés, del registroT Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumor-infiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. These T cells are clonally expanded as a result of checkpoint inhibition and are responsible for the patient's clinical response. The goal of this study is to acquire tumor and blood samples from up to 200 patients with solid tumor malignancies who respond to ICI therapy. T cells will be isolated from these samples and the targets of their TCRs determined using TScan's genome-wide, high-throughput target ID technology. The expected outcome of this study is the discovery of a collection of new targets for TCR T-cell therapy, along with associated TCRs that will then be developed as novel therapies for patients with similar malignancies.
Más ensayos de TCRX
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | no aplica | En marcha, sin reclutar | ene 2026 (prevista, ya pasada: sin actualizar en el registro) |
| SOC + TSC-101 | Fase 1 | Reclutando pacientes | jun 2026 (real) |
| TSC-204-A0201 | Fase 1 | En marcha, sin reclutar | dic 2026 (prevista) |
| TSC-101 · ALLOHA-2 | Fase 3 | Reclutando pacientes | jun 2029 (prevista) |
| LTFU | no aplica | Reclutando pacientes | sep 2040 (prevista) |
| A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease | no aplica | Completado | sep 2026 (real) |
Todos los de TCRX, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05230186), actualizada en sep 2026.